Abstract
Background: Daratumumab is a monoclonal antibody that targets CD38, which is highly expressed in lymphoid tumour cells. Daratumumab-based combinations have been incorporated as frontline therapy for multiple myeloma, and is well tolerated in clinical trials for other blood cancers. However, responses are heterogeneous and development of treatment resistance inevitable. Therefore, elucidation and targeting of mechanisms which can overcome daratumumab resistance is essential for the optimization of therapeutic response in patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
